Proteasome Inhibitors Induce Apoptosis in Ex Vivo Cells of T-Cell Prolymphocytic Leukemia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252413573 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Vanessa Rebecca Gasparini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Section, Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, 35122 Padova, Italy. Hauptthemen laut MEDLINE: Leukemia, Prolymphocytic, T-Cell, Apoptosis, Proteasome Inhibitors, Bortezomib. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research.
Abstract (Originalsprache)
Finding an effective treatment for T-PLL patients remains a significant challenge. Alemtuzumab, currently the gold standard, is insufficient in managing the aggressiveness of the disease in the long term. Consequently, numerous efforts are underway to address this unmet clinical need. The rarity of the disease limits the ability to conduct robust clinical trials, making in silico, ex vivo, and in vivo drug screenings essential for designing new therapeutic strategies for T-PLL. We conducted a drug repurposing analysis based on T-PLL gene expression data and identified proteasome inhibitors (PIs) as a promising new class of compounds capable of reversing the T-PLL phenotype. Treatment of ex vivo T-PLL cells with Bortezomib and Carfilzomib, two PI compounds, supported this hypothesis by demonstrating increased apoptosis in leukemic cells. The current lack of a suitable in vitro model for the study of T-PLL prompted us to perform similar experiments in the SUP-T11 cell line, validating its potential by showing an increased apoptotic rate. Taken together, these findings open new avenues for investigating the molecular mechanisms underlying the efficacy of PI in T-PLL and expand the spectrum of potential therapeutic strategies for this highly aggressive disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Section, Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, 35122 Padova, Italy.
- Veneto Institute of Molecular Medicine (VIMM), 35129 Padova, Italy.
- Hematology Unit, San Bortolo Hospital, 36100 Vicenza, Italy.
- Department of Molecular Medicine, University of Padova, 35122 Padova, Italy.
- Cardiology, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, 35122 Padova, Italy.
- Department of Biology, University of Padova, 35131 Padova, Italy.
ORCID-Profile: Elisa Rampazzo, Giulia Calabretto, Cristina Vicenzetto, Livio Trentin, Monica Facco, Gianpietro Semenzato, Stefania Bortoluzzi, Renato Zambello
Förderung
- Italian Association for Cancer Research
Zitieren
APA
Gasparini, V. R., Rampazzo, E., Barilà, G., Buratin, A., Buson, E., Calabretto, G., Vicenzetto, C., Orsi, S., Tonini, A., Teramo, A., Trentin, L., Facco, M., Semenzato, G., Bortoluzzi, S., & Zambello, R. (2024). Proteasome Inhibitors Induce Apoptosis in Ex Vivo Cells of T-Cell Prolymphocytic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413573
Vancouver
Gasparini VR, Rampazzo E, Barilà G, Buratin A, Buson E, Calabretto G, et al. Proteasome Inhibitors Induce Apoptosis in Ex Vivo Cells of T-Cell Prolymphocytic Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413573
BibTeX
@article{Gasparini2024,
author = {Gasparini, Vanessa Rebecca and Rampazzo, Elisa and Barilà, Gregorio and Buratin, Alessia and Buson, Elena and Calabretto, Giulia and Vicenzetto, Cristina and Orsi, Silvia and Tonini, Alessia and Teramo, Antonella and Trentin, Livio and Facco, Monica and Semenzato, Gianpietro and Bortoluzzi, Stefania and Zambello, Renato},
title = {Proteasome Inhibitors Induce Apoptosis in Ex Vivo Cells of T-Cell Prolymphocytic Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252413573}
}
EUVIMED